Navigate:低危前列腺癌患者及其伴侣在线治疗决策辅助工具随机对照试验研究方案
Navigate提供 tailored 的 unbiased 治疗选项及副作用信息与价值观澄清练习,主要结局为自报的主动监测作为一线管理的采纳率,随访至 consent 后6个月。
要点
- Navigate为在线决策辅助工具,针对澳大利亚低危前列腺癌患者及其伴侣定制。
- 主要结局为自报的主动监测作为一线管理选项的采纳率,于 consent 后1个月评估。
- 次要结局包括决策准备、决策冲突/后悔/满意度、疾病沟通质量及前列腺癌特异性生活质量。
核心结论
- Navigate在线决策辅助工具可能提高低危前列腺癌患者选择主动监测的比例,避免或延迟不必要的根治性治疗及其副作用。
- Navigate可能减少患者及伴侣在管理决策中的困惑与痛苦,并提高其生活质量。
研究设计与样本
- 纳入标准为确诊低危前列腺癌3个月内、年龄18岁及以上、尚未做出治疗决定、经治医生认为适合主动监测、有互联网接入且英语能力足够参与。
- 参与者在随机化前及研究 consent 后1、3、6个月完成结局测量。
关键数值与推荐
- 主要结局为自报的主动监测作为一线管理选项的采纳率,于 consent 后1个月通过患者自报确定。
- 次要结局包括自报的决策准备、决策冲突/后悔/满意度、疾病沟通质量及前列腺癌特异性生活质量。
- 对照组被引导至澳大利亚前列腺癌 peak national body 的网站。
- 试验注册号为 ACTRN12616001665426,注册日期2016年12月2日。
临床怎么用
- 临床可考虑使用Navigate在线决策辅助工具帮助低危前列腺癌患者及其伴侣做出与价值观一致的管理决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS) is the disease management option of choice for low-risk prostate cancer. Despite this, men with low-risk prostate cancer (LRPC) find management decisions distressing and confusing. We developed Navigate, an online decision aid to help men and their partners make management decisions consistent with their values. The aims are to evaluate the impact of Navigate on uptake of AS; decision-making preparedness; decisional conflict, regret and satisfaction; quality of illness communication; and prostate cancer-specific quality of life and anxiety. In addition, the healthcare cost impact, cost-effectiveness and patterns of use of Navigate will be assessed. This paper describes the study protocol. METHODS: Three hundred four men and their partners are randomly assigned one-to-one to Navigate or to the control arm. Randomisation is electronically generated and stratified by site. Navigate is an online decision aid that presents up-to-date, unbiased information on LRPC tailored to Australian men and their partners including each management option and potential side-effects, and an interactive values clarification exercise. Participants in the control arm will be directed to the website of Australia's peak national body for prostate cancer. Eligible patients will be men within 3 months of being diagnosed with LRPC, aged 18 years or older, and who are yet to make a treatment decision, who are deemed eligible for AS by their treating clinician and who have Internet access and sufficient English to participate. The primary outcome is self-reported uptake of AS as the first-line management option. Secondary outcomes include self-reported preparedness for decision-making; decisional conflict, regret and satisfaction; quality of illness communication; and prostate cancer-specific quality of life. Uptake of AS 1 month after consent will be determined through patient self-report. Men and their partners will complete study outcome measures before randomisation and 1, 3 and 6 months after study consent. DISCUSSION: The Navigate online decision aid has the potential to increase the choice of AS in LRPC, avoiding or delaying unnecessary radical treatments and associated side effects. In addition, Navigate is likely to reduce patients' and partners' confusion and distress in management decision-making and increase their quality of life. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry ACTRN12616001665426 . Registered on 2 December 2016. All items from the WHO Trial Registration Data set can be found in this manuscript.
引用
- Schofield P, Gough K, Hyatt A, et al. Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners. Trials. 2021. PMID: 33430950. doi:10.1186/s13063-020-04986-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。